Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial
Authors:
- 9 August 2024
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 209, 114276
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 45 references indexed in Scilit:
- Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trialsESMO Open, 2021
- Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomasClinical and Translational Oncology, 2021
- Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paragangliomaEndocrine, 2017
- Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine TumoursEndocrine Pathology, 2017
- Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomasJournal of Surgical Oncology, 2017
- Comprehensive Molecular Characterization of Pheochromocytoma and ParagangliomaCancer Cell, 2017
- SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paragangliomaInternational Journal of Cancer, 2014
- Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation statusEuropean Journal of Cancer, 2012
- Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomasCancer, 2011
- “The” pheochromocytoma: A benign, intra‐adrenal, hypertensive, sporadic unilateral tumor. Does it exist?World Journal of Surgery, 1994